EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”) plus one non-transferable contingent value right (“CVR”). Following a thorough revi ...

XOMA Royalty (XOMA) shares soared 9% in the last trading session to close at $26.22. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.2% loss over the past four weeks.The rise in the stock price can be attributed to the positive investor mindset regarding Xoma's extensive and growing portfolio of assets, defined as the right to receive potential future payments related to the advancement of an underlying therapeutic candidate. L ...

EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing ...

XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 123.08%. A quarter ago, it was expected that this drug developer would post a loss of $0.29 per share when it actually produced a loss of $0.46, delivering a surprise of -58.62%.Over the last four quarters, the ...

Financial Performance - Net income for the three months ended March 31, 2025, was $2.4 million, compared to a net loss of $8.6 million for the same period in 2024[245]. - Total income and revenues for the three months ended March 31, 2025, were $15.9 million, an increase of $14.4 million from $1.5 million in the same period in 2024[252]. - Income from purchased receivables under the EIR method for the three months ended March 31, 2025, included estimated income of $5.8 million related to sales of VABYSMO[253]. - Total other (expense) income, net for Q1 2025 was $(95,000), a decrease of $2.1 million compared to $1.96 million in Q1 2024[262]. - Investment income decreased by $0.8 million to $0.9 million in Q1 2025 due to decreased balances and market interest rates[262]. - Net cash provided by operating activities was $2.2 million in Q1 2025, an increase of $7.1 million compared to $(4.9 million) in Q1 2024[265]. - Total cash receipts for Q1 2025 were $17.96 million, up from $9.77 million in Q1 2024, driven by increased royalties from VABYSMO[267]. Expenses - R&D expenses for the three months ended March 31, 2025, were $1.3 million, a significant increase from $33 thousand in the same period in 2024[258]. - G&A expenses for the three months ended March 31, 2025, were $8.1 million, a decrease of $0.4 million from $8.5 million in the same period in 2024[259]. - The company expects to incur $0.4 million in incremental costs related to its new headquarters lease in Emeryville, California[272]. Cash and Debt - Cash and cash equivalents as of March 31, 2025, were $90.3 million, down $11.4 million from $101.7 million as of December 31, 2024[264]. - The outstanding principal balance under the Blue Owl Loan Agreement was $113.6 million as of March 31, 2025, with an annual interest rate of 9.875%[274]. Milestones and Partnerships - The company completed the sale of all five pipeline assets from the Kinnate Biopharma acquisition, eligible for up to $270 million in upfront and milestone payments[246]. - A $3.0 million milestone payment was earned from Takeda for the first patient dosed in its Phase 3 clinical trial of mezagitamab (TAK-079)[248]. - The company expects future revenue and income to be primarily based on milestone and royalty payments from existing partners and licensees[244]. - The company contributed $5.0 million to a $75.0 million royalty financing transaction for Castle Creek Biosciences, acquiring a royalty interest in a Phase 3 asset[247]. Accumulated Deficit and Tax Benefits - The accumulated deficit as of March 31, 2025, remained at $1.2 billion, unchanged from the previous year[245]. - The company had an accumulated deficit of $1.2 billion as of March 31, 2025[267]. - The company has $5.9 million in gross unrecognized tax benefits, which will not impact the effective tax rate due to a full valuation allowance[263]. Stock Repurchase - The stock repurchase program authorized up to $50 million, with $0.6 million spent to purchase 26,488 shares as of March 31, 2025[273].

Exhibit 99.1 XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen's tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immune thrombocytopenia Business development: Acquired an economic interest in Castle Creek Biosciences' D-Fi (FCX-0 ...

Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immune thrombocytopenia Business development: Acquired an economic interest in Castle Creek Biosciences’ D-Fi (FCX-007) through participation in a syndicated royalty financing transaction and successfully sold all unpartnere ...

Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET. Mr. Hughes will join the "Pros and Cons of Royalty Model – Especially in Current Financing Environment" panel discussion at 4:00 PM ET. Mr. Sitko will participate in the "Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?" panel at 5:00 PM ET. Registration for the conference can be accessed by visiting https://ct.to/wD4ms7s. XOMA Royalty's presentations can be accessed by visiting the investor relations sect ...

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, annou ...

Group 1 - XOMA Royalty Corporation focuses on acquiring royalties and milestone rights from biotech assets in early to mid-development stages [1] - The company offers a preferred stock, XOMAO, which yields a dividend of 8.375% and is cumulative [1]